An event is serious (based on the ICH definition) when the patient outcome is:
* congenital anomaly
* other medically important event
In a prospective observational study of 58 patients performed between May 2016 and September 2017, eight patients [ages and sexes not stated] were described, who developed resistance to ceftolozane/tazobactam during treatment of multidrug resistant Pseudomonas aeruginosa infection [routes, duration of treatments to reactions onset and outcomes not stated; not all doses stated].
Patient 1: A patient, who had multidrug resistant Pseudomonas aeruginosainfection, received treatment with ceftolozane/tazobactam along with meropenem, ceftazidime and amikacin. The dose of ceftolozane in ceftolozane/tazobactam was reported as 1g. A sample bronchial aspirate isolated on 18 Jul 2016 showed minimum inhibitory concentration (MIC) of ceftolozane/tazobactam 4 mg/L and on 31 Jul 2016 MIC of...
- Diaz-Canestro M, et al. Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands. European Journal of Clinical Microbiology and Infectious Diseases 37: 2191-2200, No. 11, Nov 2018. Available from: URL: http://doi.org/10.1007/s10096-018-3361-0 - SpainCrossRefGoogle Scholar